Event Brief
Gilead Acquires Ouro Medicines for Antibody Drug
Filed: Mar 24, 2026 at 5:04 AM ET
Summary: Gilead Sciences agrees to acquire Ouro Medicines for up to $2.18 billion, focusing on an antibody drug for autoimmune diseases.
WHO: Gilead Sciences
WHAT: Acquisition of Ouro Medicines
WHEN: Mar 24, 2026 at 3:51 AM ET
WHERE: USA
WHY: To enhance Gilead's drug pipeline amid patent expirations.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →